Over the past decade, peptide drug discovery has experienced a revival of interest and
scientific momentum, as the pharmaceutical industry has come to appreciate the role that …

Gastrointestinal neuroendocrine tumors are rare slow-growing tumors with distinct
histological, biological, and clinical characteristics that have increased in incidence and …

Neuroendocrine neoplasms (NENs) arise from the diffuse neuroendocrine cell system and
may occur at many different disease sites. Most frequently, these neoplasms occur in the …

Only advances that occurred from 2011 to 2014 that either strengthen the previous 2011
guidelines [1, 2] or lead to changes or additional guidelines are reviewed here. Advances …

M. Pavel a D. O'Toole b F. Costa c J. Capdevila d D. Gross e R. Kianmanesh f E. Krenning g
U. Knigge h R. Salazar i U.-F. Pape a K. Öberg j all other Vienna Consensus Conference …

Purpose: Bronchial and gastroenteropancreatic neuroendocrine tumors (NET) are slow-
growing tumors, which frequently express somatostatin receptors on their cell membranes …

The NCCN Guidelines for Neuroendocrine and Adrenal Tumors provide recommendations
for the management of adult patients with neuroendocrine tumors (NETs), adrenal gland …

Peptide receptor radionuclide therapy (PRRNT) is a molecularly targeted radiation therapy
involving the systemic administration of a radiolabelled peptide designed to target with high …

The purpose of these guidelines is to assist physicians caring for patients with
neuroendocrine neoplasia in considering eligibility criteria for peptide receptor radionuclide …

Purpose Peptide receptor radionuclide therapy (PRRT) with 90 Y and 177 Lu provides
objective responses in neuroendocrine tumours, and is well tolerated with moderate toxicity …